Literature DB >> 29294048

XPAT: a toolkit to conduct cross-platform association studies with heterogeneous sequencing datasets.

Yao Yu1, Hao Hu1, Ryan J Bohlender1, Fulan Hu1,2, Jiun-Sheng Chen1,3, Carson Holt4, Jerry Fowler1, Stephen L Guthery5, Paul Scheet1, Michelle A T Hildebrandt1, Mark Yandell4, Chad D Huff1.   

Abstract

High-throughput sequencing data are increasingly being made available to the research community for secondary analyses, providing new opportunities for large-scale association studies. However, heterogeneity in target capture and sequencing technologies often introduce strong technological stratification biases that overwhelm subtle signals of association in studies of complex traits. Here, we introduce the Cross-Platform Association Toolkit, XPAT, which provides a suite of tools designed to support and conduct large-scale association studies with heterogeneous sequencing datasets. XPAT includes tools to support cross-platform aware variant calling, quality control filtering, gene-based association testing and rare variant effect size estimation. To evaluate the performance of XPAT, we conducted case-control association studies for three diseases, including 783 breast cancer cases, 272 ovarian cancer cases, 205 Crohn disease cases and 3507 shared controls (including 1722 females) using sequencing data from multiple sources. XPAT greatly reduced Type I error inflation in the case-control analyses, while replicating many previously identified disease-gene associations. We also show that association tests conducted with XPAT using cross-platform data have comparable performance to tests using matched platform data. XPAT enables new association studies that combine existing sequencing datasets to identify genetic loci associated with common diseases and other complex traits.

Entities:  

Mesh:

Year:  2018        PMID: 29294048      PMCID: PMC5888834          DOI: 10.1093/nar/gkx1280

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  59 in total

1.  Pooled association tests for rare variants in exon-resequencing studies.

Authors:  Alkes L Price; Gregory V Kryukov; Paul I W de Bakker; Shaun M Purcell; Jeff Staples; Lee-Jen Wei; Shamil R Sunyaev
Journal:  Am J Hum Genet       Date:  2010-05-13       Impact factor: 11.025

2.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

3.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

4.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

5.  Comparison of Multi-Sample Variant Calling Methods for Whole Genome Sequencing.

Authors:  Kwangsik Nho; John D West; Huian Li; Robert Henschel; Apoorva Bharthur; Michel C Tavares; Andrew J Saykin
Journal:  IEEE Int Conf Systems Biol       Date:  2014-10

6.  Genome-wide association study identifies five new schizophrenia loci.

Authors: 
Journal:  Nat Genet       Date:  2011-09-18       Impact factor: 38.330

7.  VAAST 2.0: improved variant classification and disease-gene identification using a conservation-controlled amino acid substitution matrix.

Authors:  Hao Hu; Chad D Huff; Barry Moore; Steven Flygare; Martin G Reese; Mark Yandell
Journal:  Genet Epidemiol       Date:  2013-07-08       Impact factor: 2.135

8.  Integrated analysis of germline and somatic variants in ovarian cancer.

Authors:  Krishna L Kanchi; Kimberly J Johnson; Charles Lu; Michael D McLellan; Mark D M Leiserson; Michael C Wendl; Qunyuan Zhang; Daniel C Koboldt; Mingchao Xie; Cyriac Kandoth; Joshua F McMichael; Matthew A Wyczalkowski; David E Larson; Heather K Schmidt; Christopher A Miller; Robert S Fulton; Paul T Spellman; Elaine R Mardis; Todd E Druley; Timothy A Graubert; Paul J Goodfellow; Benjamin J Raphael; Richard K Wilson; Li Ding
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

9.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

10.  VARPRISM: incorporating variant prioritization in tests of de novo mutation association.

Authors:  Hao Hu; Hilary Coon; Man Li; Mark Yandell; Chad D Huff
Journal:  Genome Med       Date:  2016-08-25       Impact factor: 11.117

View more
  3 in total

1.  Polygenic risk impacts PDGFRA mutation penetrance in non-syndromic cleft lip and palate.

Authors:  Yao Yu; Rolando Alvarado; Lauren E Petty; Ryan J Bohlender; Douglas M Shaw; Jennifer E Below; Nada Bejar; Oscar E Ruiz; Bhavna Tandon; George T Eisenhoffer; Daniel L Kiss; Chad D Huff; Ariadne Letra; Jacqueline T Hecht
Journal:  Hum Mol Genet       Date:  2022-07-21       Impact factor: 5.121

2.  A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk.

Authors:  Yao Yu; Kyle Chang; Jiun-Sheng Chen; Ryan J Bohlender; Jerry Fowler; Di Zhang; Maosheng Huang; Ping Chang; Yanan Li; Justin Wong; Huamin Wang; Jian Gu; Xifeng Wu; Joellen Schildkraut; Lisa Cannon-Albright; Yuanqing Ye; Hua Zhao; Michelle A T Hildebrandt; Jennifer B Permuth; Donghui Li; Paul Scheet; Chad D Huff
Journal:  HGG Adv       Date:  2021-12-10

3.  Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer.

Authors:  Honglin Song; Ed M Dicks; Susan Ramus; Simon Gayther; Paul Pharoah; Jonathan Tyrer; Maria Intermaggio; Georgia Chenevix-Trench; David D Bowtell; Nadia Traficante; Aocs Group; James Brenton; Teodora Goranova; Karen Hosking; Anna Piskorz; Elke van Oudenhove; Jen Doherty; Holly R Harris; Mary Anne Rossing; Matthias Duerst; Thilo Dork; Natalia V Bogdanova; Francesmary Modugno; Kirsten Moysich; Kunle Odunsi; Roberta Ness; Beth Y Karlan; Jenny Lester; Allan Jensen; Susanne Krüger Kjaer; Estrid Høgdall; Ian G Campbell; Conxi Lázaro; Miguel Angel Pujara; Julie Cunningham; Robert Vierkant; Stacey J Winham; Michelle Hildebrandt; Chad Huff; Donghui Li; Xifeng Wu; Yao Yu; Jennifer B Permuth; Douglas A Levine; Joellen M Schildkraut; Marjorie J Riggan; Andrew Berchuck; Penelope M Webb; Opal Study Group; Cezary Cybulski; Jacek Gronwald; Anna Jakubowska; Jan Lubinski; Jennifer Alsop; Patricia Harrington; Isaac Chan; Usha Menon; Celeste L Pearce; Anna H Wu; Anna de Fazio; Catherine J Kennedy; Ellen Goode
Journal:  J Med Genet       Date:  2020-06-16       Impact factor: 5.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.